MIRA INFORM REPORT
|
Report Date : |
29.03.2007 |
IDENTIFICATION DETAILS
|
Name : |
LEE PHARMA PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
A-401, Sai Datta Apartments, Srinivasanagar
Colony East, 157, Hyderabad - 500 038, Andhra Pradesh |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2006 |
|
|
|
|
Date of
Incorporation : |
06.10.1997 |
|
|
|
|
Com. Reg. No.: |
01-28095 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24230AP1997PTC028095 |
|
|
|
|
TAN No.: [Tax Deduction
& Collection Account No.] |
HYDL00387C |
|
|
|
|
Legal Form : |
Private Limited
Liability Company |
|
|
|
|
Line of Business
: |
Manufacturing and
marketing of Active Pharmaceutical Ingredients (APIs) and Intermediate
Chemicals. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit
Limit : |
USD 300000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a
well-established company having satisfactory track. Directors are reported as
experienced, respectable and having satisfactory means of their own. Their
trade relations are reported as fair. Payments are usually correct and as per
commitments. The company can be
considered normal for business dealings at usual trade terms and conditions. |
LOCATIONS
|
Registered
Office : |
A-401, Sai Datta Apartments, Srinivasanagar
Colony East, 157, Hyderabad - 500 038, Andhra Pradesh |
|
Tel. No.: |
91-40-23751320/21 |
|
Fax No.: |
91-40-23747598 |
|
E-Mail : |
lee.pharma@gnhyd.global.net.in,
info@leeoharma.com, sales@leepharma.com, purchase@leepharma.com, accounts@leepharma.com |
|
Website : |
|
|
|
|
|
Corporate Office : |
No. 401, Saidatta
Apartments, Srinivasa Nagar Colony (East), Ameerpet, Hyderabad - 500038,
Andhra Pradesh, India |
|
Tel. No.: |
91-40-23751320/21 |
|
Fax No.: |
91-40-23747598 |
|
|
|
|
Factory 1 : |
Active
Pharmaceutical Ingredients : Survey No. 10/G-1,
Gaddapotharam Village, Ginnaram Mandal, Medak Dist., Hyderabad, Andhra
Pradesh, India |
|
E-Mail : |
Owned |
|
Area : |
14700 sq.mtr. |
|
|
|
|
Factory 2 : |
Bulk Pellets : Survey No. 199,
Plot No. 3, D. No. 5-9-265/2, Rajeev Gandhi Nagar, , Kukatpally, Hyderabad –
500 072, Andhra Pradesh Lee Advanced
Research Centre : Sy. No. 10/G/1,
Gaddapotharam Industrial Estate, Jinnaram Mandal, Medak District,
Andhra Pradesh, India |
|
Tel. No.: |
91-40-23078738/23074614 |
|
Area : |
25000 sq.ft. |
|
Location : |
Owned |
DIRECTORS
|
Name : |
Mr. A. Venkata
Reddy |
|
Designation : |
Managing Director |
|
Address : |
Plot No. 157,
Vivekanandnagar Colony, Kukatpally, Hyderabad-500072, Andhra Pradesh, India |
|
Date of Birth : |
15.02.1955 |
|
Qualification : |
Post Graduate |
|
Experience : |
26 years |
|
Date of
Appointment : |
08.10.2002 |
|
Date of Ceasing
: |
07.10.2007 |
|
|
|
|
Name : |
Mrs. A. Ratna
Kumari |
|
Designation : |
Wholetime Director |
|
Address : |
Plot No. 157,
Vivekanandnagar Colony, Kukatpally, Hyderabad-500072, Andhra Pradesh, India |
|
Date of Birth : |
22.11.1960 |
|
Qualification : |
Graduate |
|
Experience : |
18 years |
|
Date of
Appointment : |
06.10.1997 |
|
|
|
|
Name : |
Mr. B.
Satyanarayana Reddy |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. D. Kesava
Reddy |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. T. Gopala Rao |
|
Designation : |
Director |
|
Address : |
203, Siri Residency,
Thakur Mansion Lane, Somajiguda, Hyderabad-500082, Andhra Pradesh, India |
|
Date of Appointment
: |
22.04.1999 |
|
|
|
|
Name : |
Mr. Puchhalapally Mitra |
|
Designation : |
Additional Director |
|
Address : |
Flat No. 303, Padmaja
Towers, Srinagar Colony, Hyderabad-500073, Andhra Pradesh, India |
|
Tel. No.: |
91-40-55499951 |
|
Fax No.: |
91-40-23747538 |
|
E-Mail : |
|
|
Other
Directorship : |
Genova Biotechniques Private Limited CIN No.: U01110AP2001PTC036979 Designation : Chairman and Managing Director |
MAJOR SHAREHOLDERS
|
Names of Shareholders |
No. of Shares |
|
Mr. A. Venkata Reddy |
249000 |
|
Mrs. A. Ratna Kumari |
161700 |
|
Mr. A. Raghumitra |
102300 |
|
Mrs. A. Leela Rani |
62100 |
|
Mr. P. V. Subba Reddy |
16200 |
|
Mr. P. Jagadeeshwara Reddy |
4050 |
|
Mrs. P. Padmalatha Reddy |
5400 |
|
Mrs. P. Anjusha Reddy |
1350 |
|
Mr. P. Venkata Reddy |
6750 |
|
Mrs. P. Varalakshmi |
1350 |
|
Mr. P. Venkata Reddy |
2700 |
|
Dr. K. Lahiri |
100 |
|
Mrs. K. Swapna Lahiri |
100 |
|
Mrs. M. Lakshmi Prasanna |
100 |
|
Mr. P. Madhusudhan Reddy |
5400 |
|
Mr. P. Bhuvana Reddy |
5400 |
|
Mr. A. Nagi Reddy |
42700 |
|
Mrs. A. Anjamma Reddy |
40800 |
|
Mr. K. Tarun Reddy |
10000 |
|
Mr. K. Bhargav Reddy |
10000 |
|
Mr. B. Pitchi Reddy |
20000 |
|
Mrs. B. Dhanalakshmi Reddy |
15000 |
|
Mr. B. Anasurya Reddy |
15000 |
|
Mr. S. Madhusudhan Reddy |
20000 |
|
Mr. M. Mallikarjun Rao |
100 |
|
Mrs. A. Vijaya Kumari |
100 |
|
Mr. B. Rama Subba Reddy |
100 |
|
Mr. K. Mallikarhun Reddy |
100 |
|
Dr. T. Gopal Rao |
100 |
BUSINESS DETAILS
|
Line of Business
: |
Manufacturing and
marketing of Active Pharmaceutical Ingredients (APIs) and Intermediate
Chemicals. |
|
|
|
|
Products : |
Ř Intermediates Ř APIs Ř Pallets and
Granuels Ř LARC Ř Formulation Ř Bulk
Pharmaceutical Chemicals Ř Intermediate
Chemicals Ř Modified Release
Dosage Forms Apis Antihypertensive Ř Carvedilol Ř Doxazosin
Mesylate Ř Enalaprilat Ř Lisinopril Antiulcerative Ř Lansprazole
powder Ř Esomeprazole
magnesium powder Ř Omeprazole
powder Ř Omeprazole Magnesium Antifungal Ř Fluconazole Ř Itraconazole
Powder Ř Saperconazole Ř Terconazole Antidepressant Ř Citalopram HBr Ř Setraline HCI
Form I & II Ř Venlafaxine HCI
Powder Antihistaminic Ř Levocetirizine
HCI Ř bulk pellets Antiulcerative Ř Lansoprazole
Pellets Ř Esomeprazole Magnesium
Pellets Ř Omeprazole
Pellets Antidepressant Ř Venlafaxine HCL
Pellets Intermediate
Chemicals Ř 4-Hydroxy
Carbazole Ř 4-(3,3-epoxypropoxy)
Carbazole Ř 2-(2-methoxyphenoxy)
ethylamine Hydrochloride Ř 1-(1,4-benzodioxan-2-yl
carbonyl) piperazine Ř N6 –trifluoroacetyl-L-lysine Ř N2-[(1S)
– ehtoxycarbonyl-3-phenylpropyl]-n6-trifluoroacetyl-L-lysine |
|
|
|
|
Exports to : |
Mexico, Brazil,
Switzerland, Dubai, Bangladesh, Pakistan, Spain, Poland, Turkey, Korea,
Israel, Argentina, Colombia, China, Germany, Uruguay, Taiwan, Ukraine and
Canada. |
GENERAL INFORMATION
|
No. of Employees
: |
80 |
|
|
|
|
Bankers : |
State Bank of
India, Balanagar Branch,
Hyderabad, Andhra Pradesh |
|
|
|
|
Banking
Relations : |
Good |
|
|
|
|
Auditors : |
M. V. Narayana
Reddy & Company Chartered
Accountants |
|
Address : |
504, Vijayasree
Apartments, Opp. Kamma Sangam, Ameerpet, Hyderabad - 500 016, Andhra Pradesh,
India |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
900000 |
Equity Shares |
Rs.10/- each |
Rs.9.000
millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
798000 |
Equity Shares |
Rs.10/- each |
Rs.7.980
millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2006 |
31.03.2005 |
31.3.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
7.980 |
7.980 |
7.980 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
69.403 |
50.164 |
39.166 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
77.383 |
58.144 |
47.146 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
122.807 |
58.905 |
40.325 |
|
|
2] Unsecured Loans |
19.195 |
14.269 |
10.997 |
|
|
TOTAL BORROWING |
142.002 |
73.174 |
51.322 |
|
|
DEFERRED TAX LIABILITIES |
15.412 |
9.457 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
234.797 |
140.775 |
98.468 |
|
|
|
|
|
|
|
|
APPLICATION OF
FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net
Block] |
139.612 |
82.034 |
59.238 |
|
|
Capital
work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.300 |
0.000 |
|
|
DEFERREX TAX
ASSETS |
0.000 |
0.000 |
(6.960) |
|
|
|
|
|
|
|
|
CURRENT ASSETS,
LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
70.718 |
59.921 |
36.175 |
|
|
Sundry Debtors |
87.920 |
57.183 |
81.196 |
|
|
Cash & Bank
Balances |
4.610 |
5.074 |
3.608 |
|
|
Other Current
Assets |
0.000 |
0.000 |
0.000 |
|
|
Loans &
Advances |
32.362 |
13.670 |
9.115 |
|
Total Current Assets |
195.610
|
135.848 |
130.094
|
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current
Liabilities |
107.316 |
75.414 |
82.525 |
|
|
Provisions |
0.471 |
3.560 |
3.100 |
|
Total Current Liabilities |
107.787
|
78.974 |
85.625
|
|
|
Net
Current Assets |
87.823
|
56.874 |
44.469
|
|
|
|
|
|
|
|
|
MISCELLANEOUS
EXPENSES |
0.276 |
0.003 |
0.005 |
|
|
Deferred Revenue
Expenditure |
7.086 |
1.564 |
1.716 |
|
|
TOTAL |
234.797 |
140.775 |
98.468 |
|
PROFIT & LOSS ACCOUNT
|
PARTICULARS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
Sales Turnover [including other income] |
394.107 |
307.514 |
252.763 |
|
|
|
|
|
|
Profit/(Loss) Before Tax |
28.989 |
17.055 |
17.476 |
|
Provision for Taxation |
0.000 |
0.000 |
5.388
|
|
Profit/(Loss) After Tax |
28.989 |
17.055 |
12.088 |
|
|
|
|
|
|
Export Value |
NA |
NA |
140.143 |
|
|
|
|
|
|
Import Value |
NA |
NA |
15.497 |
|
|
|
|
|
|
Total Expenditure |
365.118 |
290.460 |
235.285 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
7.35
|
0.05 |
4.78
|
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
7.35
|
0.05 |
0.07
|
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
8.65
|
7.85 |
9.23
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.37
|
0.29 |
0.37
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
3.23
|
2.62 |
2.90
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.81
|
1.72 |
2.92
|
LOCAL AGENCY FURTHER INFORMATION
Form 8 Particular for creation or modification of charges
|
Name of the company |
LEE PHARMA LIMITED |
||||||||||||||||||||||||||||||||||||||||||||||||
|
Presented By |
Mr. A. Venkata Reddy Managing Director (Name and designation of the official of the
Company |
||||||||||||||||||||||||||||||||||||||||||||||||
|
1) Date and description of instrument
creating the change |
Dt.01.03.1999
(Hypothecation
of Goods, Book Debts, Movables and other Assets)
(Letter of
Credit Guarantees and Indemnities)
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
2) Amount secured by the charge/amount owing
on the securities of charge |
Working Capital Limits of Rs.4.000 Millions Term Loan of Rs.1.200 Millions |
||||||||||||||||||||||||||||||||||||||||||||||||
|
3) Short particular of the property charged.
If the property acquired is subject to charge, date of the acquired of the
property should be given |
Hypothecation of Stocks, Book Debts and
Pledge of Machinery and other equipment. Equitable mortgage of landed property in the
name of Company of Acres 1.83 Cents at Sy.No.10/G-1in Gadda Potharam Village,
Jinnaram Mandal, Medak District. Equitable mortgage of landed property in the
name of Company 0.35 Cents at Sy.No.10, Gaddapotharam Village, Jinnaram
Mandal, Mandek District. |
||||||||||||||||||||||||||||||||||||||||||||||||
|
4) Gist of the terms and conditions and
extent and operation of the charge. |
Working Capital limits shall be repayable on
demand with interest@ 3.25% above SBI advance rate subject to minimum of
16.25%. Term Loan shall be repayable in eight
quarterly instalments commencing from 01.07.1999 together with interest @
15.75% + interest tax. |
||||||||||||||||||||||||||||||||||||||||||||||||
|
5) Name and Address and description of the
person entitled to the charge. |
State Bank Of India Balanagar Branch Hyderabad-500037 |
||||||||||||||||||||||||||||||||||||||||||||||||
|
6) Date
and brief description of instrument modifying the charge |
Date: 18.10.2005 Instruments: 1. Board Resolution
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
7) Particulars of modifications specifying
the terms and conditions or the extent of operations of the charge in which
modification is made and the details of the modification. |
(Rs. in Millions)
Security
Cash Credit, EPC
(Sub Limit), Bill Discounting, Letters of Credit and Bank Guarantee:
Hypothecation of all chargeable current assets of the company. Term Loan (New):
First charge on the fixed assets being acquired with bank finance. II. Collateral
Securities:
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Rate of
Interest: Cash Credit: 0.75% above State Bank advance
rate (SBAR)- effective rate being 11.00% with monthly rests subject to change
in SBAR from time to time. EPC: Up to 180 days-6.5% per annum with
monthly rests and beyond 180 days-8.15% per annum with monthly rests. Bill Discounting: Up to 180 days- 6.5% per
annum with monthly rests and beyond 180 days-8.15% per annum with monthly
rests. Term Loan (New): 2% over SBAR – effective rate
being 12.25% with monthly rests subject to change in SBAR from time to time. Term Loan (New) is repayable in 59 monthly
equal instalments of Rs.0.534 millions starting from October 2006 to August
2011. Interest payable as when applied. SLC: Interest rate equivalent to 1% over the
present applicable rate on Cash Credit (current effective rate 12%) would be
charged. |
|
Name of the company |
LEE PHARMA PRIVATE LIMITED |
||||||||||||||||||||||||||||||||||||
|
Presented By |
Mr. A. Venkata Reddy Managing Director (Name and designation of the official of the
Company |
||||||||||||||||||||||||||||||||||||
|
1) Date and description of instrument
creating the change |
Dt.01.03.1999
(Hypothecation of Goods, Book
Debts, Movables and other Assets)
(Letter of
Credit Guarantees and Indemnities)
|
||||||||||||||||||||||||||||||||||||
|
2) Amount secured by the charge/amount owing
on the securities of charge |
Working Capital Limits of Rs.4.000 Millions Term Loan of Rs.1.200 Millions |
||||||||||||||||||||||||||||||||||||
|
3) Short particular of the property charged.
If the property acquired is subject to charge, date of the acquired of the
property should be given |
Hypothecation of Stocks, Book Debts and
Pledge of Machinery and other equipment. Equitable mortgage of landed property in the
name of Company of Acres 1.83 Cents at Sy.No.10/G-1in Gadda Potharam Village,
Jinnaram Mandal, Medak District. Equitable mortgage of landed property in the
name of Company 0.35 Cents at Sy.No.10, Gaddapotharam Village, Jinnaram
Mandal, Mandek District. |
||||||||||||||||||||||||||||||||||||
|
4) Gist of the terms and conditions and
extent and operation of the charge. |
Working Capital limits shall be repayable on
demand with interest@ 3.25% above SBI advance rate subject to minimum of
16.25%. Term Loan shall be repayable in eight
quarterly instalments commencing from 01.07.1999 together with interest @
15.75% + interest tax. |
||||||||||||||||||||||||||||||||||||
|
5) Name and Address and description of the
person entitled to the charge. |
State Bank Of India Balanagar Branch Hyderabad-500037 |
||||||||||||||||||||||||||||||||||||
|
6) Date
and brief description of instrument modifying the charge |
Date: 18.10.2005 Instruments: 1. Arrangement Letter
|
||||||||||||||||||||||||||||||||||||
|
7) Particulars of modifications specifying
the terms and conditions or the extent of operations of the charge in which
modification is made and the details of the modification. |
(Rs. in Millions)
Security Primary
Securities: Cash
Credit: Hypothecation of Stocks and Book Debts. Term
Loan : Hypothecation of Plant and Machinery purchased from Bank finance. II.
Collateral Securities:
|
||||||||||||||||||||||||||||||||||||
|
|
Rate of
Interest: Cash Credit: (Hypothecation of Stocks/ Book
Debts/ Outward Bills) 0.75% above State Bank advance rate (SBAR)- effective
rate being 11.00% per annum with monthly rests. SBAR at present is 10.25% and
is subject to change from time to time. EPC: 3.15% below State Bank Short Term
Advances Rate (SBAR) with minimum of 7.10% and is subject to change from time
to time. Repayment of Term Loan 59 Equal instalments
of Rs.0.534 millions starting from 01.10.2005 or 6 months after completion of
the project which ever is less and 60th instalment of Rs.0.494
millions. Interest payable as and when applied. Rate of Interest @ 2.00 and
above State Bank Advances Rate (SBAR) with minimum of 12.25% per annum with
monthly rests. At present SBAR is 10.25% and is subject to change from time
to time. |
|
Name of the company |
LEE PHARMA PRIVATE LIMITED |
|||||||||||||||||||||||||||||||||||||||
|
Presented By |
Mr. A. Venkata Reddy Managing Director (Name and designation of the official of the
Company |
|||||||||||||||||||||||||||||||||||||||
|
1) Date and description of instrument
creating the change |
Dt.01.03.1999
(Hypothecation of Goods, Book
Debts, Movables and other Assets)
(Letter of
Credit Guarantees and Indemnities)
|
|||||||||||||||||||||||||||||||||||||||
|
2) Amount secured by the charge/amount owing
on the securities of charge |
Working Capital Limits of Rs.4.000 Millions Term Loan of Rs.1.200 Millions |
|||||||||||||||||||||||||||||||||||||||
|
3) Short particular of the property charged.
If the property acquired is subject to charge, date of the acquired of the
property should be given |
Hypothecation of Stocks, Book Debts and Pledge
of Machinery and other equipment. Equitable mortgage of landed property in the
name of Company of Acres 1.83 Cents at Sy.No.10/G-1in Gadda Potharam Village,
Jinnaram Mandal, Medak District. Equitable mortgage of landed property in the
name of Company 0.35 Cents at Sy.No.10, Gaddapotharam Village, Jinnaram
Mandal, Mandek District. |
|||||||||||||||||||||||||||||||||||||||
|
4) Gist of the terms and conditions and
extent and operation of the charge. |
Working Capital limits shall be repayable on
demand with interest@ 3.25% above SBI advance rate subject to minimum of
16.25%. Term Loan shall be repayable in eight
quarterly instalments commencing from 01.07.1999 together with interest @
15.75% + interest tax. |
|||||||||||||||||||||||||||||||||||||||
|
5) Name and Address and description of the
person entitled to the charge. |
State Bank Of India Balanagar Branch Hyderabad-500037 |
|||||||||||||||||||||||||||||||||||||||
|
6) Date
and brief description of instrument modifying the charge |
Date: 24.02.2005 Instruments: 1. Letter of Sanction of Credit Facilities.
|
|||||||||||||||||||||||||||||||||||||||
|
7) Particulars of modifications specifying
the terms and conditions or the extent of operations of the charge in which
modification is made and the details of the modification. |
(Rs. in Millions)
Security Primary
Securities: Cash
Credit: Hypothecation of Stocks and Book Debts. Term
Loan : Hypothecation of Plant and Machinery purchased from Bank finance. II.
Collateral Securities:
|
|||||||||||||||||||||||||||||||||||||||
|
|
Rate of
Interest: Cash Credit: (Hypothecation of Stocks/ Book Debts/
Outward Bills) 0.75% above State Bank advance rate (SBAR) with minimum of
11.00% per annum with monthly rests. SBAR at present is 10.25% and is subject
to change from time to time. EPC: 3.15% below State Bank Short Term
Advances Rate (SBAR) with minimum of 7.10% and is subject to change from time
to time. Repayment of Term Loan 59 Equal instalments
of Rs.0.534 millions starting from 01.10.2005 or 6 months after completion of
the project which ever is less and 60th instalment of Rs.0.494
millions. Interest payable as and when applied. Rate of Interest @ 2.00 and
above State Bank Advances Rate (SBAR) with minimum of 12.25% per annum with
monthly rests. At present SBAR is 10.25% and is subject to change from time
to time. Funds utilised from the Standby line of
Credit (SLC), interest rate equivalent to 1% over the present applicable rate
(current effective rate 12%) would be charged. |
Web site Details :
Over the years, they have leveraged their position in the global market
with an enviable list of clients and a phenomenal growth rate achieved through
product innovation, dedicated teams and timely implementation of solutions.
They believe in
Quality and Customer Satisfaction. Their experience and expertise ensures their
business gains competitive edge over others competition. They follow the right
methodology for each scenario thereby generating substantial value to their
customers by reducing time-to-market and ensuring a high level of
predictability in time, cost and quality.
Lee pharma meets to all the standards, quality methodologies and other
scientifically derived technologies to become a leader in the Pharma world.
Management
Mr A.Venkata
Reddy – Managing Director
A Post Graduate in
Economics and has a rich experience of more than 26 years in Pharmaceutical
Industry. Started his Career with Dr. Reddy’s group of Companies & served
in various capacities till 1993. Co-promoter of Hetero Drugs Limited, Served in
the capacity of Executive Director till 1996. Promoter of M/S Genix Pharma and served
in the capacity of Managing Director till 1997. Started M/s Lee Pharma in 1997.
Mrs. A.Ratna
Kumari - Director - Q.A
A Graduate in Chemistry and had
experience of 18 years as Quality Assurance In-charge and is the instrumental
in setting up quality Control Systems & Experienced in the implementation
of Regulatory Affairs.
Dr. T.
Gopala Rao – Director
Well known medical practitioner in Hyderabad, India with the specialization in
urology. Who is associated with Lee Pharma from the inception of the company
for advising the Pharmacology studies for APIs.
At Global level, the
Bulk Drug Industry is passing through the changeover situation and new
strategic alliances, mergers and take overs are taking place by identifying the
strength of each company and joining hands to fully utilise the opportunities
to the growth rate in the new millennium. During this process, the year 2005 AD
is an important milestone year for the Indian Pharmaceutical Industry. Since
the Indian Industry is going to be covered under the patent laws.
To meet the
challenges in the new millennium, the company has established the basic
research centre under the name and style "Lee Advanced Research
Centre". A number of scholars are working in the invention of critical
health care molecules to make available for the needy.
Marketing of Solutions
Marketing is more
about solutions than products. The company's experience has been that for a
hundred specific healthcare needs being addressed by different products there
are always a few that are being overlooked. The company's special expertise has
been in identifying niche and special needs and developing solutions for them.
It is this inventiveness that helped it gain the confidence of its growing
clientele. In the future too, the company shall seek to address critical
healthcare applications.
Looking Forward
The company fruition
of plans and actions it has taken in a short, but eventful, period of
operations. The company has devised a blueprint for exploring several exciting
new areas, researching and developing new molecules, biosynthesis, synergistic
alliances with leading Indian & World players in developing new products
etc. Sharing knowledge and experience not just with customers but its
competitors too, the company believes, enriches everyone involved.
Press Clippings
Brazilian
panel approves Lee Pharma's product
Lee Pharma (Private) Limited, a Hyderabad based pharmaceutical company
has got accreditation for its product Omeprazole as a reference standard by Brazilian Pharmaceutical Committee. "This rare recognition is rated as the quality of the
Indian products as a reference standard by the International
pharmacoepia," said S. L.
P Raju, Vice president, Lee Pharma.
Lee Pharma is
engaged in manufacturing of active pharmaceutical ingredients, mainly
anti-ulceratives, cardiac category and anti-fungal range of products.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.43.59 |
|
UK Pound |
1 |
Rs.85.53 |
|
Euro |
1 |
Rs.58.14 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|